eter Larsen watched a discouraging cycle of pharmaceutical companies touting a new treatment for Alzheimer’s only to be followed by a failed drug trial. So he considered another approach.

The Duke University biologist, who studies mouse lemurs that have symptoms resembling Alzheimer’s, co-authored a paper with a Duke neurologist that considers whether the science behind failed Alzheimer’s drugs incorrectly equated the buildup of amyloid plaques — a waxy protein inside the brain — with a cause of the memory-destroying disease rather than a symptom. Called the “amyloid hypothesis,” this line of thinking has been called into question with the recent failures of drugs targeting amyloid.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy